AMRX Stock Analysis: Amneal Pharmaceuticals | NASDAQ

Generics, Injectables, Biosimilars, Neurology

Total Rating 58

Safety 70

Buy Signal 1.33

Drug Manufacturers - Specialty & Generic
Industry Rotation: +3.3

Market Cap: 6.95B
Avg Turnover: 87.9M

Risk 3d forecast

Volatility36.4%

VaR 5^th Pctl6.05%

VaR vs Median0.82%

Reward TTM

Sharpe Ratio1.84

Rel. Str. IBD95.9

Rel. Str. Peer Group88.1 pctl

Character TTM

Beta0.227

Beta Downside-0.477

Hurst Exponent0.562

Choppyness53.6%

Drawdowns 3y

Max DD24.65%

CAGR/Max DD2.90

CAGR/Mean DD9.86

EPS (Earnings per Share)

EPS CAGR: 19.72%
EPS Trend: 89.1%

Last SUE: 0.28
Qual. Beats: 0

Revenue

Rev. CAGR: 10.36%
Rev. Trend: 98.6%

Last SUE: 2.64
Qual. Beats: 2

Warnings

No concerns identified

Tailwinds

Shakeout

Rs Leader

Idiosyncratic Leader

Avwap Ph Week

Seasonality 11.7 years of data

Jan +1.8% 8

Feb +0.3% 7

Mar -3.6% 35

Apr -3.0% 21

May +2.5% 17

Jun -3.2% 16

Jul +0.5% 7

Aug +9.3% 9

Sep -2.0% 5

Oct -2.2% 0

Nov -1.2% 0

Dec -0.2% 2

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: AMRX Amneal Pharmaceuticals

Amneal Pharmaceuticals (AMRX) is a U.S.-based global biopharmaceutical company that develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products across the United States, India, Ireland, and other international markets. Founded in 2002 and headquartered in Bridgewater, New Jersey, the company operates through three reporting segments: Affordable Medicines, Specialty, and AvKARE.

The Affordable Medicines segment covers a broad range of dosage forms and delivery systems, including immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilars, ophthalmics, films, transdermal patches, and topicals. The Specialty segment focuses on central nervous system and endocrine disorders, with a particular emphasis on Parkinsons disease, offering branded products such as Rytary (an oral capsule formulation of carbidopa-levodopa), Unithroid, ONGENTYS, and CREXONT. The AvKARE segment supplies pharmaceuticals, medical and surgical products, and services primarily to U.S. government agencies, including the Department of Defense and the Department of Veterans Affairs, distributing products under the AvKARE and AvPAK labels.

Amneal sells through a diversified channel network that includes wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was originally incorporated as Atlas Holdings, Inc. and adopted its current name in 2018. Within the highly competitive generics and biosimilars sector, Amneal combines a high-volume, cost-driven generics business with a targeted specialty branded portfolio and a government-focused distribution arm.

Headlines to Watch Out For

CREXONT Parkinsons drug launch drives specialty segment growth
Generic pricing erosion pressures Affordable Medicines margins
AvKARE government contract revenue expands with DoD and VA demand

Piotroski VR-10 (Strict) 3.0

Net Income: 147.5m TTM > 0 and > 6% of Revenue
FCF/TA: 0.01 > 0.02 and ΔFCF/TA -6.03 > 1.0
NWC/Revenue: 30.52% < 20% (prev 33.27%; Δ -2.75% < -1%)
CFO/TA 0.03 > 3% & CFO 182.6m > Net Income 147.5m
Net Debt (3.25b) to EBITDA (667.8m): 4.86 < 3
Current Ratio: 1.87 > 1.5 & < 3
Outstanding Shares: last quarter (335.7m) vs 12m ago 3.38% < -2%
Gross Margin: 40.24% > 18% (prev 36.76%; Δ 3.48% > 0.5%)
Asset Turnover: 72.08% > 50% (prev 81.53%; Δ -9.45% > 0%)
Interest Coverage Ratio: 2.12 > 6 (EBIT TTM 474.3m / Interest Expense TTM 223.6m)

Altman Z'' 1.72

A: 0.19 (Total Current Assets 2.10b - Total Current Liabilities 1.12b) / Total Assets 5.27b
B: -0.10 (Retained Earnings -535.0m / Total Assets 5.27b)
C: 0.11 (EBIT TTM 474.3m / Avg Total Assets 4.43b)
D: 0.11 (Book Value of Equity 531.3m / Total Liabilities 4.63b)
Altman-Z'' = 1.72 = BBB

Beneish M -2.81

DSRI: 1.01 (Receivables 1.02b/924.1m, Revenue 3.20b/2.93b)
GMI: 0.91 (GM 36.76% / 40.24%)
AQI: 1.37 (AQ_t 0.46 / AQ_t-1 0.34)
SGI: 1.09 (Revenue 3.20b / 2.93b)
TATA: -0.01 (NI 147.5m - CFO 182.6m) / TA 5.27b)
Beneish M = -2.81 (Cap -4..+1) = A

What is the price of AMRX shares?

As of November 10, 2026, the stock is trading at USD 21.28 with a total of 2,604,199 shares traded. Over the past week, the price has changed by +4.11%, over one month by +6.88%, over three months by +19.02% and over the past year by +85.37%.

Current recommended Stop Loss: 20.20 (which is 5.1% or 1.3 ATR below the current price).

Is AMRX a buy, sell or hold?

Amneal Pharmaceuticals has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy AMRX.

StrongBuy: 4
Buy: 3
Hold: 0
Sell: 0
StrongSell: 0

What are the forecasts/targets for the AMRX price?

Analysts Target Price	23.4	10.1%

Amneal Pharmaceuticals (AMRX) - Fundamental Data Overview as of 06 November 2026

Market Cap USD = 6.95b (6.95b USD * 1.0 USD.USD)
P/E Trailing = 49.875
P/E Forward = 17.4825
P/S = 2.1743
P/B = 215.5757
P/EG = 1.9411
Revenue TTM = 3.20b USD
EBIT TTM = 474.3m USD
EBITDA TTM = 667.8m USD
Long Term Debt = 2.57b USD (from longTermDebt, last fiscal year)
Short Term Debt = 225.6m USD (from shortTermDebt, last quarter)
Debt = 3.40b USD (from shortLongTermDebtTotal, last quarter) + Leases 121.5m
Net Debt = 3.25b USD (calculated: Debt 3.40b - CCE 157.4m)
Enterprise Value = 10.2b USD (6.95b + Debt 3.40b - CCE 157.4m)
Interest Coverage Ratio = 2.12 (Ebit TTM 474.3m / Interest Expense TTM 223.6m)
EV/FCF = 252.3x (Enterprise Value 10.2b / FCF TTM 40.4m)
FCF Yield = 0.40% (FCF TTM 40.4m / Enterprise Value 10.2b)
FCF Margin = 1.26% (FCF TTM 40.4m / Revenue TTM 3.20b)
Net Margin = 4.62% (Net Income TTM 147.5m / Revenue TTM 3.20b)
Gross Margin = 40.24% ((Revenue TTM 3.20b - Cost of Revenue TTM 1.91b) / Revenue TTM)
Gross Margin QoQ = 38.73% (prev 42.01%)
Tobins Q-Ratio = 1.94 (Enterprise Value 10.2b / Total Assets 5.27b)
Interest Expense / Debt = 6.57% (Interest Expense 223.6m / Debt 3.40b)
Taxrate = 5.40% (12.0m / 221.5m)
NOPAT = 448.7m (EBIT 474.3m * (1 - 5.40%))
Current Ratio = 1.87 (Total Current Assets 2.10b / Total Current Liabilities 1.12b)
Debt / Equity = 6.41 (Debt 3.40b / totalStockholderEquity, last quarter 531.3m)
Debt / EBITDA = 4.86 (Net Debt 3.25b / EBITDA 667.8m)
Debt / FCF = 80.36 (Net Debt 3.25b / FCF TTM 40.4m)
Total Stockholder Equity = 112.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.33% (Net Income 147.5m / Total Assets 5.27b)
RoE = 131.7% (Net Income TTM 147.5m / Total Stockholder Equity 112.0m)
RoCE = 17.72% (EBIT 474.3m / Capital Employed (Equity 112.0m + L.T.Debt 2.57b))
RoIC = 10.64% (NOPAT 448.7m / Invested Capital 4.22b)
WACC = 6.34% (E(6.95b)/V(10.4b) * Re(6.41%) + D(3.40b)/V(10.4b) * Rd(6.57%) * (1-Tc(0.05)))
Discount Rate = 6.41% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 85.67 | Cagr: 2.30%
[DCF] Terminal Value 73.10% ; FCFF base≈122.2m ; Y1≈107.1m ; Y5≈86.6m
[DCF] Fair Price = N/A (negative equity: EV 1.39b - Net Debt 3.25b = -1.86b; debt exceeds intrinsic value)
EPS Correlation: 89.08 | EPS CAGR: 19.72% | SUE: 0.28 | # QB: 0
Revenue Correlation: 98.62 | Revenue CAGR: 10.36% | SUE: 2.64 | # QB: 2
EPS current Quarter (2027-03-31): EPS=0.25 | Chg30d=+0.80% | Revisions=-25% | Analysts=5
EPS current Year (2026-12-31): EPS=1.03 | Chg30d=+0.93% | Revisions=+25% | GrowthEPS=+24.4% | GrowthRev=+5.9%
EPS next Year (2027-12-31): EPS=1.21 | Chg30d=+1.75% | Revisions=+25% | GrowthEPS=+17.5% | GrowthRev=+9.2%
[Analyst] Revisions Ratio: +17% (up=2, down=1)